Acurx Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021

Aug 31, 2021

Acurx Pharmaceuticals, Inc. Reports Second Quarter 2021 Results and Provides Business Update

Aug 16, 2021

Acurx Pharmaceuticals to Present at the Emerging Growth Conference on August 18, 2021

Aug 12, 2021

Acurx Pharmaceuticals Joins the Antimicrobials Working Group

Aug 5, 2021

Health Holland Awards Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals

Aug 2, 2021

Acurx Pharmaceuticals to Discuss 2021 Second Quarter Financial Results on August 17, 2021 Conference Call and Provide Business Update

Jul 28, 2021

Acurx Announces Filing of Provisional Patent Application for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving the Health of the Gut Microbiome

Jul 7, 2021

Acurx Announces New Ibezapolstat Data on Anti-Recurrence Mechanisms in CDI at Prominent International Conference

Jul 1, 2021

ACURX PHARMACEUTICALS, Inc. Announces Closing of INITIAL Public Offering OF common stock AND FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES

Jun 29, 2021

Acurx Pharmaceuticals, Inc. announces pricing of $15 Million underwritten Initial public offering of common stock

Jun 25, 2021